Premium
Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma
Author(s) -
Aguilera Dolly G.,
Goldman Steward,
Fangusaro Jason
Publication year - 2011
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22868
Subject(s) - medicine , irinotecan , bevacizumab , refractory (planetary science) , regimen , medulloblastoma , clinical trial , oncology , salvage therapy , surgery , chemotherapy , cancer , colorectal cancer , pathology , physics , astrobiology
Relapsed/refractory medulloblastoma (MB) has a poor outcome regardless of the treatment employed. Novel therapies are needed in an effort to improve survivals. We present two children with recurrent/refractory MB treated with bevacizumab and irinotecan both given every 2 weeks. One patient also received temozolamide. The first patient had stable disease and remains without progression after 30 months. The second patient had a near complete response that was sustained for 18 months. The regimen was well tolerated with minimal toxicity and provided prolonged progression‐free survival in these two patients. Prospective clinical trials are needed to evaluate the effectiveness of this strategy. Pediatr Blood Cancer 2011;56:491–494. © 2010 Wiley‐Liss, Inc.